West Pharmaceutical Services (WST) Non-Current Debt (2009 - 2026)

West Pharmaceutical Services (WST) has reported Non-Current Debt for 18 consecutive years, with $202.9 million the latest figure, recorded in Q2 2026.

• Quarterly Non-Current Debt changed 0.15% year-over-year to $202.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $202.9 million (changed 0.15% YoY) and the FY2025 annual result came in at $202.8 million, changed 0.1% from the prior year.
• Non-Current Debt steadied at $202.9 million in Q2 2026 per WST's latest filing, from $202.8 million in the prior quarter.
• Over the last five years, Non-Current Debt for WST reached as high as $252.5 million in Q1 2022 and fell as low as $202.6 million in Q3 2024.
• A 5-year average of $210.4 million and a median of $206.0 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt slipped 17.59% — and 2026, when it advanced 0.15%.
• Year by year, Non-Current Debt stood at $208.9 million in 2022, then decreased by 1.01% to $206.8 million in 2023, then fell by 2.03% to $202.6 million in 2024, then rose by 0.1% to $202.8 million in 2025, then advanced by 0.05% to $202.9 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $202.9 million, $202.8 million, and $202.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.